期刊文献+

B细胞活化因子/增殖诱导配体与紫癜性肾炎的研究进展 被引量:3

Progress of B lymphocyte activating factor/a proliferation inducing ligand in Henoch-Schonlein purpura nephritis
原文传递
导出
摘要 紫癜性肾炎(Henoch-Schonlein purpura nephritis,HSPN)是儿童最常见的继发性肾小球疾病,其发病机制尚未明确.近年来有研究表明肿瘤坏死因子家族新成员B细胞活化因子(B lymphocyte activaring factor,BAFF)和增殖诱导配体(a proliferation inducing ligand,APRIL)与HSPN发病相关.该文将从BAFF和APRIL的结构和生物学功能、BAFF和APRIL在HSPN发病中的作用、BAFF和APRIL靶向生物制剂治疗HSPN的展望等方面进行综述,为探讨HSPN发病机制提供参考. Henoch-schonlein purpura nephritis(HSPN)is the most common secondary glomerular disease in children.The pathogenesis of HSPN is unclear.In recent years,there have been some reports on B lymphocyte activating factor(BAFF)and a proliferation inducing ligand(APRIL),new members of the tumor necrosis factor family,as well as their association with HSPN.This paper reviews the related research from the following aspects:structure and biological functions of BAFF and APRIL,the role of BAFF/APRIL in the pathogenesis of HSPN,the prospect of BAFF and APRIL targeted biological agents in the treatment of HSPN.It provides a reference for further research on BAFF/APRIL system and HSPN.
作者 朱万红(综述) 吴玉斌(审校) Zhu Wanhong;Wubin(Department of Pediatrics,Shengjing Hospital of China Medical University,Shenyang 110004,China)
出处 《国际儿科学杂志》 2018年第12期933-937,共5页 International Journal of Pediatrics
关键词 紫癜性肾炎 B细胞活化因子 增殖诱导配体 Henoch-schonlein purpura nephritis B lymphocyte activating factor A proliferation inducing ligand
作者简介 通信作者:吴玉斌,Email:euyb@sj-hospital.org
  • 相关文献

参考文献3

二级参考文献22

  • 1Tullus K, Marks S D. Vasculitis in children and adolescents: clinical presentation, etiopathogenesis, and treatment [ J ]. Paediatr Drugs, 2009;11 (6) :375-380.
  • 2Khan W N. B cell receptor and BAFF receptor signaling regulation of B cell homeostasis [ J ]. J Immunol, 2009 ; 1 83 ( 6 ) : 3561-3567.
  • 3Schmitt R, Carlsson F, Morgelin M et al. Tissue deposits of IgA- binding streptococcal M proteins in IgA nephropathy and Henoch- Schonlein purpura[ J]. Am J Pathol, 2010;176(2) : 608-618.
  • 4Mackay F, Schneider P. Cracking the BAFF code [ J ]. Nat Rev Im- munol,2009,9 (7) :491-502.
  • 5Davidson A. Targeting BAFF in autoimmunity[ J]. Curr Opin Immu- nol,2010,22(6) :732-739.
  • 6Ramanujam M. Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice[J]. Arthritis Rheum,2010,62(5) :1457-1468.
  • 7Jacob CO. Paucity of clinical disease despite serological autoirranunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice de- ficient in BAFF[J]. J Immunol,2006,177(4) :2671-2680.
  • 8Liu Z, A Davidson. BAFF inhibition: a new class of drugs for the treatment of autoimmunity [ J ]. Exp Cell Res, 2011,317 ( 9 ) : 1270- 1277.
  • 9Halpern WG. Chronic administration of belimumab, a BLyS antago- nist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys : pharmacokinetic, pharmacodynamic and toxicologic effects[ J]. Toxicol Sci,2006,91 (2) :586-599.
  • 10Auyeung-Kim DJ. Developmental and peri-postnatal study in cyno- molgus monkeys with belimumab, a monoclonal antibody directed a- gainst B-lymphocyte stimulator [ J ]. Reprod Toxicol, 2009,28 ( 4 ) : 4.4-3 -455.

共引文献12

同被引文献38

引证文献3

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部